Protembis Announces FDA Approval of its Pivotal Investigational Device Exemption (IDE) Study

Contributed by: Business Wire

Logo

Tags

General Health

Professional Services

Venture Capital

Medical Devices

Hospitals

Small Business

Clinical Trials

Cardiology

Biotechnology

Finance

FDA

Health

FDA Approval Investigational Device Exemption IDE Study

More Like This

Protembis Announces First Patient Enrolled in the PROTEMBO IDE Pivotal Trial

Protembis Announces Completion of € 30 Million Series B Financing Round and the Addition of Keith D Dawkins MD to the Board of Directors

The ProtEmbo Cerebral Embolic Protection system in the Aortic Arch (Graphic: Business Wire)

German Medtech Protembis Gets €20 Million EIB Backing for Technology to Protect Brain During Heart Treatment

PR Newswire associated0

New Published Study Demonstrates Safety and Feasibility of Filterlex Medical's CAPTIS® Device in Providing Embolic Protection During TAVR

Emboline, Inc. Files Patent Infringement Suit Against AorticLab s.r.l. Regarding Embolic Protection Medical Device

PR Newswire associated0

Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S.

Rapid Medical™ Announces Japanese Approval and Exclusive Partnership With Kaneka for TIGERTRIEVER–The World’s Only Adjustable Thrombectomy Device

Rapid Medical™ Reports No Safety Concerns for Medium Vessel Occlusions in the Interim Safety Analysis of the DISTALS Study with TIGERTRIEVER™13